B. Riley Cuts Lantheus (NASDAQ:LNTH) Price Target to $109.00

Lantheus (NASDAQ:LNTH) had its price target reduced by B. Riley from $122.00 to $109.00 in a research note published on Monday,Benzinga reports. B. Riley currently has a buy rating on the medical equipment provider’s stock.

Several other equities research analysts also recently weighed in on the stock. Wall Street Zen upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Lantheus currently has a consensus rating of “Buy” and an average target price of $130.50.

Lantheus Stock Performance

Shares of LNTH stock opened at $80.55 on Monday. The firm has a market cap of $5.57 billion, a price-to-earnings ratio of 22.88 and a beta of 0.11. The company’s 50 day moving average is $85.53 and its 200 day moving average is $90.83. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. Lantheus has a 52-week low of $73.11 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to analysts’ expectations of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The business’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.69 earnings per share. On average, sell-side analysts anticipate that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the business’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director now directly owns 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LNTH. Sanctuary Advisors LLC lifted its position in Lantheus by 58.5% during the fourth quarter. Sanctuary Advisors LLC now owns 18,042 shares of the medical equipment provider’s stock valued at $1,674,000 after purchasing an additional 6,656 shares during the period. Lingotto Investment Management LLP lifted its position in Lantheus by 61.4% during the fourth quarter. Lingotto Investment Management LLP now owns 89,232 shares of the medical equipment provider’s stock valued at $7,983,000 after purchasing an additional 33,958 shares during the period. Parkside Financial Bank & Trust lifted its position in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares during the period. Chase Investment Counsel Corp acquired a new position in Lantheus during the fourth quarter valued at $1,431,000. Finally, Bridges Investment Management Inc. lifted its position in Lantheus by 98.9% during the fourth quarter. Bridges Investment Management Inc. now owns 12,070 shares of the medical equipment provider’s stock valued at $1,080,000 after purchasing an additional 6,001 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.